Literature DB >> 6250746

Serum ferritin in patients with cancer: determination with antibodies to HeLa cell and spleen ferritin.

B M Jones, M Worwood, A Jacobs.   

Abstract

Some malignant tissues and cell lines contain acidic isoferritins and it has been suggested that the assay of such isoferritins in serum may be of value in the diagnosis of malignancy. This paper describes a radioimmunoassay for acidic ferrtin purified from HeLa cells. Examiniation of purified heart, kidney, liver and spleen ferritin showed that the assay was highly specific for acidic isoferritins. Ferritin concentrations have been measured with antibodies to HeLa cell and spleen ferritin in extracts of normal and tumour tissue. Although the tumours contained more HeLa type ferritin than the corresponding normal tissue the HeLa/spleen type ferritin ratio was low. HeLa-type ferritin concentrations have been compared with values obtained with anti-spleen ferritin in over 1000 sera from normal subjects and patients with cancer and leukaemia. HeLa-type ferritin as not detected ( less than 2 micrograms/l) in most normal sera. Concentrations of up to 53 micrograms/l were found in sera from patients with malignant disease but the HeLa/spleen type ferritin ratio was always very low. There appears to be little application for antibodies to HeLa cell or heart ferritin in the diagnosis or monitoring of cancer.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6250746     DOI: 10.1016/0009-8981(80)90173-4

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  12 in total

1.  Placental isoferritin associated p43 antigen correlates with features of high differentiation in breast cancer.

Authors:  H R Rosen; C Moroz; A Reiner; M Reinerova; M Stierer; J Svec; M Schemper; R Jakesz
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

2.  Assignment of human ferritin genes to chromosomes 11 and 19q13.3----19qter.

Authors:  M Worwood; J D Brook; S J Cragg; B Hellkuhl; B M Jones; P Perera; S H Roberts; D J Shaw
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

Review 3.  Plasma ferritin determination as a diagnostic tool.

Authors:  C A Finch; V Bellotti; S Stray; D A Lipschitz; J D Cook; M J Pippard; H A Huebers
Journal:  West J Med       Date:  1986-11

4.  Serum ferritin and binding of serum ferritin to concanavalin A as a tumor marker in patients with primary liver cell cancer and chronic liver disease.

Authors:  R W Chapman; M F Bassendine; M Laulicht; A Gorman; H C Thomas; S Sherlock; A V Hoffbrand
Journal:  Dig Dis Sci       Date:  1982-02       Impact factor: 3.199

5.  Identification of leukemia-associated inhibitory activity as acidic isoferritins. A regulatory role for acidic isoferritins in the production of granulocytes and macrophages.

Authors:  H E Broxmeyer; J Bognacki; M H Dorner; M de Sousa
Journal:  J Exp Med       Date:  1981-06-01       Impact factor: 14.307

Review 6.  Serum ferritin and malignant tumours.

Authors:  A Jacobs
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

7.  Basic isoferritin and hypercalcaemia in renal cell carcinoma.

Authors:  G J Mufti; T J Hamblin; J Stevens
Journal:  J Clin Pathol       Date:  1982-09       Impact factor: 3.411

8.  Placental isoferritin (PLF) in comparison with MCA and CEA in advanced breast cancer--first data from a pilot study.

Authors:  M Stierer; H R Rosen; E Forster; C Moroz
Journal:  Breast Cancer Res Treat       Date:  1991-11       Impact factor: 4.872

9.  Ferritin, finger clubbing, and lung disease.

Authors:  J M Shneerson; B M Jones
Journal:  Thorax       Date:  1981-09       Impact factor: 9.139

10.  Elevation in inflammatory serum biomarkers predicts response to trastuzumab-containing therapy.

Authors:  Ahmed A Alkhateeb; Kim Leitzel; Suhail M Ali; Cynthia Campbell-Baird; Matthew Evans; Eva-Maria Fuchs; Wolfgang J Köstler; Allan Lipton; James Connor
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.